Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1475 of 3499 entries
View as:

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01116648 Org: User:
Start: 04/14/10 End: 02/13/26 Due: 02/13/27

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01841723 Org: User:
Start: 04/30/13 End: 12/31/29 Due: 12/31/30

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01627041 Org: User:
Start: 09/16/11 End: - Due: -

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT00052208 Org: User:
Start: 03/31/02 End: - Due: -

Diet and Nutrition Pilot Study for Chinese Adolescents and Their Mothers

Phase: N/A Priority: Normal
NCT ID: NCT01517139 Org: User:
Start: 03/01/12 End: 08/27/13 Due: 08/27/14

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00513292 Org: User:
Start: 07/31/07 End: 02/21/13 Due: 02/21/14

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Phase: N/A Priority: Normal
NCT ID: NCT00923247 Org: User:
Start: 02/19/09 End: 12/09/16 Due: 12/09/17

Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance

Phase: N/A Priority: Normal
NCT ID: NCT00026663 Org: User:
Start: 08/09/00 End: 06/28/24 Due: 06/28/25

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03914612 Org: User:
Start: 08/22/19 End: 05/08/26 Due: 05/08/27

Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00435214 Org: User:
Start: 01/29/07 End: 04/30/20 Due: 04/30/21

Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01195415 Org: User:
Start: 06/30/10 End: 10/10/14 Due: 10/10/15

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

Phase: N/A Priority: Normal
NCT ID: NCT00678132 Org: User:
Start: 04/24/08 End: 11/23/10 Due: 11/23/11

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00126555 Org: User:
Start: 03/31/05 End: 02/28/13 Due: 02/28/14

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00005908 Org: User:
Start: 06/30/00 End: 01/31/08 Due: 01/31/09

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01142401 Org: User:
Start: 05/26/10 End: 01/08/21 Due: 01/08/22

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01445379 Org: User:
Start: 10/01/07 End: 11/13/15 Due: 11/13/16

E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia

Phase: N/A Priority: Normal
NCT ID: NCT04411134 Org: User:
Start: 05/28/20 End: 07/14/20 Due: 07/14/21

ZD6474 to Treat Advanced Brain Cancer in Patients

Phase: N/A Priority: Normal
NCT ID: NCT00272350 Org: User:
Start: 12/29/05 End: 02/27/14 Due: 02/27/15

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05828082 Org: User:
Start: 10/16/23 End: 06/18/26 Due: 06/18/27

Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05521698 Org: User:
Start: 04/23/25 End: 07/15/27 Due: 07/15/28

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Phase: N/A Priority: Normal
NCT ID: NCT06385483 Org: User:
Start: 02/28/18 End: 12/31/25 Due: 12/31/26

Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00002912 Org: User:
Start: 01/31/97 End: - Due: -

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03602586 Org: User:
Start: 12/21/18 End: 03/27/24 Due: 03/27/25

Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00058240 Org: User:
Start: 04/30/03 End: 02/28/09 Due: 02/28/10

Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00079274 Org: User:
Start: 02/29/04 End: 11/30/12 Due: 11/30/13